Bavarian Nordic, the maker of the only FDA-approved vaccine for mpox, experienced record revenue due to skyrocketing demand for its product during the outbreak. As a result, the company has chosen to focus on infectious disease and is discontinuing its cancer vaccine development. The decision comes after their cancer vaccine candidate reached Phase 1 testing for chordoma or HER2-positive breast cancer. The company’s focus on infectious diseases has been profitable, with a 124% increase in revenue in 2023 compared to 2022, largely driven by sales of their mpox vaccine. Dropping its cancer R&D also avoids potential competition with other companies further along in cancer vaccine development, such as BioNTech and Moderna.
Source link
Bavarian Nordic Hones Infectious Disease Focus by Dropping Cancer Vaccine R&D
